Thromboembolism and Major Bleeding in Patients with Atrial Fibrillation and EHRA Type 2 Valvular Heart Disease: The Jordan Atrial Fibrillation (JoFib) Study.

Mahasen Al-NajarMohammed Al-NusairNasr AlrabadiIbrahim AlawaishehTuqa Alawaisheh Mohamad Ismail Jarrah Karem H AlzoubiSumaya NjemAyman J Hammoudeh

Published in: Vascular health and risk management (2023)

AF patients with EHRA type 2 VHD are at significant risk of thromboembolism and major bleeding. Furthermore, NOACs were more effective than VKAs in preventing thromboembolic events in this group of patients without conferring an added risk of major bleeding. Moreover, rivaroxaban appears to be particularly efficacious.

Keyphrases

atrial fibrillation
oral anticoagulants
catheter ablation
left atrial
left atrial appendage
direct oral anticoagulants
heart failure
end stage renal disease
newly diagnosed
ejection fraction
percutaneous coronary intervention
chronic kidney disease
pulmonary hypertension
patient reported outcomes
aortic valve